X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing aims to support Blacksmith to focus on the development of FG-2101, its novel non-hydroxamate LpxC inhibitor, using both intravenous and oral administration for the treatment of urinary tract infections caused by multidrug-resistant Gram-negative bacteria.
Lead Product(s): FG-2101
Therapeutic Area: Infections and Infectious Diseases Product Name: FG-2101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $3.3 million Upfront Cash: Undisclosed
Deal Type: Funding February 21, 2024
Details:
The Blacksmith metalloenzyme platform, a focused library of metal-binding pharmacophores with proprietary computational modeling, approaches to rapidly and rationally design small molecule inhibitors that interact with key metal ions in the enzyme's active site.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Forge Therapeutics, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 02, 2023
Details:
Blacksmith and Lilly will collaborate on up to 5 human metalloenzyme targets, with Blacksmith advancing novel small molecule inhibitors from fragment to 'hit' stage after which Lilly has the right to continue research, development, and commercialization.
Lead Product(s): Metalloenzyme-targeted medicines
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
